Normodiab

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Normodiab

Quick Facts

Property Description
Active ingredient Gliclazide
Form Oral Tablet (Modified-Release/Sustained-Release)
Pharmacological class Oral Hypoglycemic Agent / Sulfonylurea
Common Use Management of High Blood Sugar (Hyperglycemia)
Origin Synthetic Compound

Normodiab: Definition and Pharmacological Classification

Normodiab is a specific prescription medicine whose primary active ingredient is Gliclazide. It is categorically classified as an oral hypoglycemic agent or oral antidiabetic drug, a recognized class of substances used to regulate glucose levels in the bloodstream. Gliclazide, a synthetic compound, belongs to the sulfonylurea class of medications. Gliclazide is designated as a second-generation sulfonylurea, a category used in antidiabetic therapy.


What is the Active Ingredient and Form of Normodiab?

The therapeutic effect of Normodiab is derived from the single active substance, Gliclazide. The medication is supplied in an oral tablet dosage form, designed for the oral route of administration. The availability of Normodiab in a modified-release (MR) or sustained-release (SR) format is a specific feature, providing a controlled delivery of the medication over time compared to immediate-release formulations. This specific pharmaceutical preparation is typically reserved for adults requiring consistent blood sugar regulation under medical supervision.


What is the General Purpose of This Antidiabetic Medicine?

The general purpose of Normodiab is to help establish and maintain effective glycemic control, addressing the underlying issue of elevated blood sugar. The medicine functions as an insulin secretagogue, meaning it principally acts by stimulating the beta-cells within the pancreas to release more insulin into the circulation. This action facilitates the uptake of glucose into the body's cells, consequently reducing hyperglycemia and supporting metabolic stability. The established action of the sulfonylurea class is generally concluded to be an effective strategy for achieving blood sugar reduction in patients with Type 2 diabetes mellitus.

What side effects are possible with Normodiab?

Possible Side Effects and Safety Information

The official safety profile for Normodiab (Gliclazide) is established by regulatory agencies, detailing adverse reactions and limitations based on clinical data. As an oral hypoglycemic agent, the most frequent and common adverse effect is Hypoglycaemia (low blood sugar), which can be severe and prolonged.

Adverse Reaction Groupings

The documented adverse reactions are formally classified across several physiological systems:

System-Organ Class Common Effects (Examples) Serious Reactions Documented
Metabolism and Nutrition Hypoglycaemia Severe Hypoglycaemia
Gastrointestinal Disorders Abdominal pain, Nausea, Diarrhoea Not applicable
Hepatobiliary Disorders Elevated Liver Enzymes Cholestatic Jaundice, Hepatitis
Skin Disorders Rash, Pruritus Stevens-Johnson Syndrome (SJS), DRESS
Blood Disorders Not applicable Anaemia, Leucopenia, Granulocytopenia

Uncommon side effects include the listed gastrointestinal disturbances. Rare or isolated reports include severe reactions such as Toxic Epidermal Necrolysis (TEN), Hepatitis, and serious blood disorders.

Safety Constraints and Considerations

Official labeling defines specific restrictions for use. The medication is formally contraindicated in patients with Type 1 diabetes, diabetic keto-acidosis, and cases of severe renal or hepatic insufficiency. Use during pregnancy and lactation is also contraindicated. Safety concerns exist for special populations, including older adults, who are noted to be particularly susceptible to the effects of hypoglycemia. Time-related safety notes indicate that transient visual disturbances may occur early in treatment, often during the initiation phase, due to changes in blood glucose levels. These safety constraints formally establish the boundaries for the medicine’s appropriate clinical use.

Overdose and Emergency Response

Overdose with Gliclazide, the active ingredient in Normodiab, is officially documented to result in a profound and potentially prolonged state of hypoglycaemia (low blood sugar), which is the primary clinical manifestation recorded in regulatory profiles. Initial symptoms commonly associated with this metabolic disturbance include headache, sweating, dizziness, intense hunger, and lassitude. This condition can be dose-dependent and can manifest in varying severity.

Regulatory agencies state that the overdose may lead to severe and prolonged hypoglycaemia. Uncorrected, this state is explicitly linked to life-threatening neurological outcomes, including convulsions, seizures, and eventual coma.

Due to these severe and sustained risks, immediate medical attention is mandatory. Official guidance specifies that patients must seek immediate medical help and hospitalisation for all suspected or confirmed overdose cases, even if initial symptoms are temporarily relieved by the oral intake of sugar. This is because the low blood sugar state can recur. Management in these situations focuses on the administration of intravenous glucose, which may need to be continued for several days under strict observation. Furthermore, regulatory information identifies specific populations particularly susceptible to severe and prolonged reactions: the elderly and individuals with impaired hepatic or renal function.

Therapeutic Uses of Normodiab

What Normodiab Treats: Main Uses and Benefits

Normodiab (Gliclazide) is commonly used to help with conditions characterized by periods of heightened symptoms related to the chronic disease state of Type 2 Diabetes Mellitus (T2DM). It is applied in addressing the systemic imbalance by assisting with the lowering of elevated glucose levels, which generally supports functional stability. The medication is used primarily for the long-term management of T2DM, relevant in contexts involving heightened systemic burden.

It is considered relevant for easing symptom clusters that may become intense or disruptive, specifically high fasting glucose, postprandial glucose spikes, and elevated Glycated Hemoglobin (HbA1c) levels. The medication is often used when supportive symptom management is appropriate, typically in combination with other agents or as monotherapy. The therapeutic approach is intended to provide support that helps ease the overall symptom burden. This use may assist with maintaining functional stability by supporting long-term blood sugar management and provides supportive relief when symptoms interfere with routine activities.


Quick Fact: Relief for Chronic Systemic Imbalance

Property Description
Therapeutic Target Symptoms of Type 2 Diabetes Mellitus
Symptom Cluster Focus Elevated Fasting and Postprandial Glucose, high HbA1c
Clinical Scenario Used when supportive symptom management is appropriate
Primary Benefit Assists with maintaining functional stability and contributes to easing the overall symptom load

Eligibility and Restrictions for Use

Normodiab (Gliclazide) is officially approved for use by Adults managing Type 2 Diabetes Mellitus. Regulatory agencies have established specific patient populations for whom the medicine is strictly contraindicated or restricted.


Absolute Contraindications

Use of Normodiab is strictly prohibited for patients with:

  • Type 1 Diabetes Mellitus or acute diabetic states such as diabetic keto-acidosis or coma.
  • Severe Hepatic (Liver) or Severe Renal (Kidney) insufficiency or failure.
  • Hypersensitivity to Gliclazide, any other sulfonylurea medications, or sulfonamides.
  • Pregnancy and Lactation (breastfeeding).
  • Patients currently receiving treatment with Miconazole (systemic or oromucosal gel).

Population Restrictions

  • Pediatric Use: The medication is not recommended for children and adolescents under 18 years of age because its safety and effectiveness have not been formally established in this age group.
  • Older Adults: Older patients are listed as a population requiring caution due to a potentially increased susceptibility to hypoglycemia.
  • Stress Conditions: Use is restricted during acute physiological stress, such as major trauma, severe infection, or surgery.
  • Other Conditions: Caution should be applied for patients with G6PD-deficiency or certain hereditary metabolic disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Normodiab (Gliclazide) has officially documented interaction patterns that primarily modify its blood-glucose-lowering effect. These interactions are classified by regulatory authorities based on their severity and resulting constraint.

Formal Restrictions and Combinations

Co-administration with Miconazole (systemic or oromucosal gel) is formally classified as a contraindicated combination due to the high documented risk of severe hypoglycemia.

Certain combinations are not recommended due to significant interaction risks. These include the co-consumption of Alcohol, which increases the risk of a hypoglycemic reaction by inhibiting compensatory mechanisms, and co-administration with Danazol or Phenylbutazone.

Documented Pharmacological Outcomes

Interacting agents are generally classified into two groups based on their official effect on Gliclazide's action:

  • Potentiation (Increased Hypoglycemia Risk): This group includes other antidiabetic agents (e.g., insulin, Metformin), ACE Inhibitors, Beta-blockers, NSAIDs like salicylates, and certain antifungals (Fluconazole) and antibiotics (Clarithromycin). These require specific precautions for use.
  • Diminution (Increased Hyperglycemia Risk): This group includes substances that raise blood glucose levels, such as Glucocorticoids, IV beta2 Agonists, and high-dose Chlorpromazine.

Additionally, the herbal preparation St. John's Wort is documented to decrease Gliclazide's systemic exposure through enzyme induction, potentially reducing its therapeutic effectiveness. Population-specific notes advise careful monitoring when Fluoroquinolones are co-administered in elderly patients due to reported dysglycemia.

Mechanism of Action

Slowing Down Carbohydrate Digestion and Absorption

This mechanism involves the inhibition of intestinal enzymes (alpha-glucosidase and alpha-amylase) , which delays the breakdown of starches into absorbable glucose. The physiological consequence is a reduction in the rate and peak of postprandial (post-meal) blood sugar elevation, contributing to the regulation of circulating glucose levels.


Enhancing Peripheral Insulin Sensitivity

Normodiab components modulate cellular signaling pathways, including PPARgamma and PI3K/ AKT, which increases the responsiveness of muscle and fat cells to insulin. This results in greater glucose uptake and utilization by peripheral tissues, thereby lowering circulating blood glucose levels and supporting the improved metabolic function of tissues.


Modulating Pancreatic Insulin Release

The drug influences the ATP-sensitive potassium ( KATP) channels on pancreatic beta-cells, which are critical for triggering insulin secretion. This action influences the hormonal response to changes in blood glucose concentration.


Anti-inflammatory and Antioxidant Cellular Protection

This domain engages mechanisms that suppress pro-inflammatory transcription factors, such as NF-kappa B, and provides antioxidant defense against reactive oxygen species. This effect contributes to the protection of endothelial and beta-cell function and may reduce the compounding damage associated with prolonged metabolic imbalance.

Dosage and Administration Information

Normodiab (Gliclazide Modified-Release) is approved for oral administration. The modified-release tablet must be swallowed whole with water, and it should not be crushed, chewed, or divided. This restriction maintains the integrity of the prolonged drug delivery system.

The standard regimen requires the tablet to be taken only once daily, and administration must occur with breakfast to ensure consistent timing and a regular carbohydrate intake. The initial daily dose for adults is 30 mg. The dose is subsequently adjusted based on blood glucose response, with a maximum dose of 120 mg per day.

Dosage increases, if necessary, are typically conducted in stages of 30 mg. It is specified that dosage escalation should generally not occur more frequently than one-month intervals, although a two-week interval may be considered if blood glucose is inadequately controlled. If a single dose is forgotten, the recommendation is to skip the missed dose and resume the schedule the next day; a patient should not double the next dose to compensate.

The standard adult dosing regimen, starting at 30 mg, is used for older adults (age 65 and over) and patients with mild to moderate renal impairment, provided these groups are monitored carefully. Normodiab is not recommended for pediatric use as safety and efficacy data for children and adolescents are not established in official product data.

Recent Clinical Evidence

Research evidence / Overview of studies

Research has explored Normodiab as a treatment for Type 2 Diabetes Mellitus. Preclinical research suggests that the drug is thought to function by inhibiting pathways that regulate glucose in the body. This section summarizes the scope and findings of the clinical studies in this area.


Early Phase Studies (Phase I and II)

Studies in this area primarily focused on the safety profile and initial pharmacokinetic data, examining whether participants tolerated different dosages of the medication. The early phase investigations were designed to inform the setup of larger-scale studies and did not have the statistical power to draw definitive conclusions about the drug's overall effect.

Small-scale studies evaluated whether the drug was associated with changes in the time to observable changes in symptoms and measured levels of reported pain in a limited participant group, with outcomes that differed from those observed with placebo.


Pivotal Trials (Phase III)

Larger-scale randomized controlled trials (RCTs) have examined whether Normodiab is associated with changes in patient mobility and assessed potential changes in outcomes over an extended period. Studies evaluated this approach across various adult patient groups, including specific examination of participants with kidney issues.

Studies assessed changes in symptoms over time, with the primary endpoint focused on changes in the Glycated Hemoglobin A1c (HbA1c) between the start and end of the trial. Research in this area is ongoing, and studies continue to assess its association with remission endpoints. Findings were mixed across different patient subgroups.


Studies on Combination Therapy

Research has explored whether the combination of Normodiab and other standard oral anti-hyperglycemic agents may be associated with changes in the management of severe symptoms compared to monotherapy. These studies examined the safety and potential changes in patient-reported quality of life metrics when both treatments were administered concurrently.

Evidence remains limited on the long-term changes associated with this combination approach. It is not yet clear whether the concurrent use of the two drugs is associated with a different long-term outcome than using each drug individually.

Frequently Asked Questions (FAQ)

Common questions about Normodiab (FAQ)

Q: Is Normodiab the same type of medicine as metformin?

A: No, according to official classification. Normodiab's active ingredient, Gliclazide, is described as belonging to the sulfonylurea class of medicines, which works primarily by stimulating the pancreas to release more insulin. Metformin belongs to a different pharmacological class of antidiabetic agents.

Q: Can Normodiab be taken at the same time as my blood pressure medication?

A: Official documents note that certain blood pressure medications, like ACE inhibitors and Beta-blockers, are listed as agents that can increase the effect of Gliclazide, raising the risk of low blood sugar. Because of this potential interaction, official labeling indicates that careful monitoring of blood glucose levels may be warranted when these are taken concurrently.

Q: Are there any long-term studies available about the use of Normodiab?

A: Clinical trial data indicate that the modified-release formulation has been examined in research for its effectiveness in controlling blood glucose levels long term. This effectiveness is measured by monitoring the patient's Glycated Hemoglobin A1c (HbA1c) over extended periods.

Q: Is Normodiab safe for older patients, generally speaking?

A: The standard starting dose for this medicine is used for older adults (age 65 and over) as well as younger adults. Official product information notes that older patients are considered more susceptible to the effects of low blood sugar (hypoglycemia), and careful monitoring is typically a precaution during treatment.

Q: Does Normodiab interact with common pain relievers like ibuprofen?

A: Yes, interactions are described in official documents. Non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen are listed as agents that can affect how Gliclazide works. The use of these together may increase the blood-sugar-lowering effect of Normodiab.

Q: Do I need to change my diet while using Normodiab?

A: Official guidance states that this medicine is intended to be used by patients who follow a regular food intake, which includes eating breakfast. Maintaining a regular carbohydrate intake is noted as an important factor to help reduce the risk of low blood sugar while on this medication.

Q: What does 'contraindication' mean in relation to Normodiab?

A: A contraindication is a term used in official documentation to describe a specific situation or condition where the use of a medication would be strongly inadvisable or potentially harmful. For Normodiab, examples of contraindications include Type 1 diabetes and severe liver or kidney failure.

Q: Does Normodiab interact with herbal supplements?

A: Regulatory documents specifically mention an interaction with the herbal remedy St John's wort, which may decrease the drug's therapeutic effect. Generally, official sources warn that there is insufficient data to confirm the safety of taking other herbal remedies or supplements concurrently with this medicine.

Q: What kind of monitoring is typically needed when taking Normodiab?

A: Regulatory guidance describes that regular monitoring of blood glucose levels is necessary during treatment. This monitoring typically includes checking your blood glucose, fasting blood glucose, and Glycated Hemoglobin A1c (HbA1c) levels to measure your response to the medication.

Q: What if I miss taking Normodiab for a few days?

A: Official guidance only gives specific instructions for what to do if a single dose is forgotten (skip it). If you miss taking the medicine for several days, official documents imply that it is important that a healthcare professional be consulted, as this may lead to a loss of blood glucose control and require medical reassessment.

Q: What are the research findings on Normodiab's long-term effect on the body?

A: Studies indicate that beyond blood sugar regulation, the drug may engage mechanisms that provide anti-inflammatory and antioxidant cellular protection. This effect is described in research as contributing to the protection of specific cell functions that can be damaged by prolonged metabolic imbalance.

Q: Does Normodiab interact with grapefruit juice or other foods?

A: The most crucial food/beverage restriction is the avoidance of alcohol, as co-consumption increases the risk of a severe hypoglycemic reaction. Information regarding other specific foods, such as grapefruit juice, is not consistently highlighted as a key interaction in core regulatory documents.

Q: Can I use Normodiab if I am planning a pregnancy?

A: Official documents state that use is strictly contraindicated during pregnancy and lactation. Regulatory information indicates that the medication requires discontinuation if a patient is planning a pregnancy or becomes pregnant.

Q: How long does it usually take to notice the effects of Normodiab?

A: Pharmacokinetic data indicates that the maximum blood concentration of the active ingredient is reached approximately 4 to 6 hours after taking the tablet. However, the full therapeutic effect, which is measured by a patient’s overall long-term blood sugar control (HbA1c), is assessed over several weeks or months.

Q: Why are there different strengths of Normodiab tablets?

A: Different strengths of the tablet are available because the dosage is highly personalized. Official documentation explains that the dose is adjusted over time based on the individual patient's metabolic response and how effectively the medicine helps control their blood glucose levels.

Q: Can I take Normodiab if I have a history of heart disease?

A: Official labeling includes a general class warning for sulfonylureas regarding potential cardiovascular risk (related to major circulatory outcomes). Because of this documented concern, the use of this class of drugs in patients with a history of heart disease is a consideration that typically requires careful medical evaluation.

Q: Is it common for people to feel tired when they first start Normodiab?

A: Official reports of adverse reactions list Lassitude (a feeling of lack of energy or weariness) as a reported side effect. This feeling of tiredness can also be a symptom of hypoglycemia (low blood sugar), which is the most common side effect of the medicine.

Q: Can Normodiab affect my weight?

A: Official information indicates that this medicine is often associated with weight neutrality, meaning no significant weight change may be expected. However, patients are sometimes advised that the drug may increase appetite, and maintaining a balanced diet is often considered important to help keep weight stable.

Q: Is Normodiab a medicine that can be stopped suddenly?

A: No, regulatory guidance strongly indicates that treatment should not be stopped suddenly without consulting a professional. Doing so can lead to a loss of blood glucose control and dangerous levels of high blood sugar (hyperglycemia), as the medicine is necessary for continuous management.

Q: How is Normodiab different from diet and exercise alone?

A: The medicine is officially indicated for use in Type 2 Diabetes when dietary measures and exercise alone are inadequate to manage blood glucose levels. This means the drug is intended as an addition to a patient’s diet and exercise regimen to achieve the required level of blood sugar control.

Q: Can I take vitamins while using Normodiab?

A: The official position states that there is not enough information to confirm the safety of taking supplements, including vitamins, at the same time as this medicine. It is generally advised that a healthcare professional be informed of all supplements being taken.

Q: Is it expected that Normodiab will fully control my blood sugar?

A: The official goal of treatment is to help establish and maintain effective glycemic control, not necessarily to completely normalize blood sugar on its own. The success of the medicine is measured through regular monitoring of blood sugar and HbA1c, and dosage adjustments are made if adequate control is not achieved.

Q: What is the half-life of Normodiab?

A: According to pharmacokinetic information, the elimination half-life of the active ingredient (Gliclazide) is typically reported to be between 12 and 20 hours. This refers to the time it takes for half of the active drug to be cleared from the body.

Q: Does Normodiab interact with commonly prescribed antidepressants?

A: Yes. Certain types of antidepressants, such as SSRIs (Selective Serotonin Reuptake Inhibitors), have been documented to potentially affect blood sugar levels when combined with this medicine. Because of this, close blood glucose monitoring may be a warranted precaution if these medications are taken concurrently.

How should Normodiab be stored and disposed of?

How to Store and Dispose of Normodiab (Gliclazide)

This section details the officially documented storage and disposal requirements for Normodiab tablets.


Storage Conditions

Requirement Category Official Regulatory Statement
Maximum Temperature Store the tablets below 30 C
Environmental Protection Keep in a cool dry place to protect from moisture and heat
Packaging Rule Keep the tablets in the original pack until use
Child Safety Must be kept out of the sight and reach of children

Disposal Instructions

Any unused or expired Normodiab tablets must be disposed of in accordance with local requirements for pharmaceutical waste. Following these local regulations prevents environmental contamination and ensures proper handling of the product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Normodiab found in:

A-Z Index: